항정신약물을 복용 중인 조현병 환자에서 성기능 장애의 유병률 조사 = Prevalence of Sexual Dysfunction in Schizophrenic Patients Taking Antipsychotic Drugs

다국어 초록 (Multilingual Abstract)

Objectives : Sexual dysfunction is said to affect the compliance of drug and quality of life. This study is a research to investigate the prevalence of sexual dysfunction and affecting factors that can occur when schizophrenic and schizoaffective patients have taken drugs.
Methods : Subjects were 300 patients who have been taken inpatient or outpatient treatment in national seoul hospital. We used UKU-S, ASEX scale for evaluating the prevalence of sexual dysfunction and CGI-S, PANSS negative scale and CES-D for investigating the influence of psychopathology and depressive symptoms on sexual dysfunction.
Results : It was reported sexual dysfunction 82.7% in male and 92.2% in female with 7 items of UKU-S. The prevalence of sexual dysfunction with criteria of ASEX was 47.72% in male and 65.05% in female. Sexual dysfunction was more prevalent in patients taking prolactin-elevation drugs. In the factor analysis for the sexual dysfunction it was investigated that age, onset time, CGI-S, PANSS negative scale, and CES-D can affect the sexual dysfunction in both male and female.
Conclusion : This study reported that many patients complained of sexual dysfunction. On considering the influence of sexual dysfunction to compliance and quality of life, clinicians evaluate sexual side effects more actively because patients are more likely not spontaneously tell the sexual side effects in comparison to others.

참고문헌 (Reference)

1 이가희, "항정신병약물을 복용중인 정신분열병 환자에서 고프로락틴혈증과 무월경 유병률 및 성기능 장애와 관련성" 대한신경정신의학회 48 (48): 422-428, 2009

2 Kay SR, "The positive and negative syndrome scale (PANSS) for schizophrenia" 13 : 261-276, 1987

3 Crawford AM, "The acute and longterm effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations" 26 : 41-54, 1997

4 Lingjaerde O, "The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients" 76 : 1-100, 1987

5 Radloff LS, "The CES-D scale: a self-report depression scale for research in the general population" 1 : 385-401, 1977

6 McGahuey CA, "The Arizona Sexual Experience Scale (ASEX): reliability and validity" 26 : 25-40, 2000

7 Gopalakrishnan R, "Sildenafil in the treatment of antipsychotic-induced erectile dysfunction: a randomized, double-blind, placebo-controlled, flexible-dose, two-way crossover trial" 163 : 494-499, 2006

8 Harley EW, "Sexual problems in schizophrenia:prevalence and characteristics. A cross sectional survey" 45 : 759-766, 2010

9 Smith S, "Sexual dysfunction-the forgotten taboo" 25 : 6-9, 2005

10 Westheide J, "Sexual dysfunction in psychiatric inpatients the role of antipsychotic medication" 40 : 140-145, 2007

11 Uçok A, "Sexual dysfunction in patients with schizophrenia on antipsychotic medication" 22 : 328-333, 2007

12 Smith SM, "Sexual dysfunction in patients taking conventional antipsychotic medication" 181 : 49-55, 2002

13 Fujii A, "Sexual dysfunction in Japanese patients with schizophrenia treated with antipsychotics" 34 : 288-293, 2010

14 Hou CL, "Sexual dysfunction and its impact on quality of life in Chinese patients with schizophrenia treated in primary care" 65 : 116-121, 2016

15 McCabe MP, "Risk factors for sexual dysfunction among women and men:a consensus statement from the fourth international consultation on sexual medicine 2015" 13 : 153-167, 2016

16 Choi YT, "Review of sexual dysfunction in male schizophrenics" 7 : 85-98, 2000

17 Martha S, "Rating scales in mental health" Lexi-comp 376-378, 2006

18 Tauscher-Wisniewski S, "Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade" 63 : 992-997, 2002

19 Guy W, "Psychiatric Measures" APA 2000

20 Fric M, "Prolactin levels and symptoms of hyperprolactinaemia in patients treated with amisulpride, risperidone, olanzapine and quetiapine" 30 : 97-101, 2003

21 Rettenbacher MA, "Prolactin levels and sexual adverse effects in patients with schizophrenia during antipsychotic treatment" 30 : 711-715, 2010

22 Richard GP, "Prolactin and antipsychotic medications: mechanism of action" 35 : 67-73, 1999

23 Dossenbach M, "Prevalence of sexual dysfunction in patients with schizophrenia: international variation and underestimation" 8 : 195-201, 2005

24 Yasui-Furukori N, "No association between hormonal abnormality and sexual dysfunction in Japanese schizophrenia patients treated with antipsychotics" 27 : 82-89, 2012

25 Olfson M, "Male sexual dysfunction and quality of life in schizophrenia" 66 : 331-338, 2005

26 Seeman MV, "Loss of libido in a woman with schizophrenia" 170 : 471-475, 2013

27 Montejo AL, "Incidence of sexual dysfunction associated with antidepressant agents:a prospective multicenter study of 1022 outpatients" 62 : 10-21, 2001

28 Mah PM, "Hyperprolactinemia: etiology, diagnosis, and management" 20 : 365-374, 2002

29 Schwartz MF, "Hyperprolactinemia and sexual disorders in men" 17 : 861-876, 1982

30 Harrison WM, "Effects of antidepressant medication on sexual function:a controlled study" 6 : 144-149, 1986

31 American Psychiatric Association, "Diagnostic and statistical manual of mental disorders: DSM-IV-TR" American Psychiatric Association 2000

32 Byerly M, "Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives" 27 : 639-661, 2007

33 Woods SW, "Chlorpromazine equivalent doses for the newer atypical antipsychotics" 64 : 663-667, 1899

34 Bushe C, "Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics" 22 : 56-62, 2008

35 Kane JM, "Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine" 68 : 213-223, 2007

36 Compton MT, "Antipsychotic-induced hyperprolactinemia and sexual dysfunction" 36 : 143-164, 2001

37 Costa AM, "A systematic review on clinical management of antipsychotic-induced sexual dysfunction in schizophrenia" 124 : 291-297, 2006